BIND Therapeutics, Inc. (NASDAQ: BIND) a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the three-month period ended September 30, 2013.
“In the third quarter, BIND made significant progress, including the initiation of two Phase 2 studies of our proprietary lead Accurin, BIND-014, in non-small cell lung cancer and metastatic castrate-resistant prostate cancer,” said Scott Minick, BIND’s President and CEO.
Help employers find you! Check out all the jobs and post your resume.
